- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Swissray lands $40 million OEM deal
Digital x-ray may represent the future for Swiss x-ray manufacturerSwissray, but it is conventional radiography that is the company'sbread and butter for the time being. Swissray announced this monththat it has signed an agreement to supply conventional
Digital x-ray may represent the future for Swiss x-ray manufacturerSwissray, but it is conventional radiography that is the company'sbread and butter for the time being. Swissray announced this monththat it has signed an agreement to supply conventional x-ray equipmentto a major multinational OEM in a deal valued at $40 million.
Swissray, of Hitzkirch, Switzerland, burst on the U.S. medicalimaging scene at last year's Radiological Society of North Americameeting with AddOn-Bucky, a device to digitize conventional x-rayexams (SCAN 12/13/95). Swissray began installing the first AddOn-Buckyunits earlier this year in Europe.
Swissray has not neglected its conventional x-ray program,however, as evidenced by this month's deal. According to the termsof the agreement, Swissray will supply its radiography productsto the OEM, which will market the devices under its own label.Swissray said that the terms of the agreement precluded it fromdisclosing the name of the OEM.
Swissray will supply equipment to the OEM for the next fourand a half years, with initial shipments to be delivered in thenext 12 months valued at over $8 million.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI Have an Impact with Fertility-Sparing Treatments for Endometrial and Cervical Cancers?
January 9th 2025In a literature review that includes insights from recently issued guidelines from multiple European medical societies, researchers discuss the role of magnetic resonance imaging (MRI) in facilitating appropriate patient selection for fertility-sparing treatments to address early-stage endometrial and cervical cancer.
